Johnson & Johnson (JNJ) Stock Forecast & Price Target

Johnson & Johnson
Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson recently reported strong second-quarter results, beating analyst expectations with earnings per share of $2.90 against a consensus estimate of $2.84, while revenue of $25.31 billion also exceeded forecasts, demonstrating robust operational performance and profitability with a net margin of 21.48%.
• The company maintains a highly attractive dividend profile, having declared a quarterly dividend of $1.34 per share with an annualized yield of approximately 1.93%, supported by a 64-year record of consecutive dividend growth that appeals to income-oriented investors seeking stability.
• Wall Street sentiment remains supportive with a consensus rating of Moderate Buy and a price target of $272.83, which is close to the current stock price of $275.12, indicating that analysts view the stock as fairly valued with potential for further appreciation as recent upgrades from firms like UBS and Morgan Stanley have boosted institutional confidence.
• Johnson & Johnson exhibits low volatility relative to the broader market with a beta of 0.24, making it a defensive holding that can provide portfolio stability during periods of market uncertainty, as evidenced by its ability to outperform the S&P 500 significantly over the past year.
• Institutional investors continue to show confidence in the company, with several major funds increasing their positions in the second quarter, such as OMERS Administration Corp raising its stake by nearly 140%, suggesting that professional money managers view the company's diversified healthcare portfolio as a long-term value driver.